Capital Rx vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 52)
Capital Rx logo

Capital Rx

ChallengerHealthcare

Pharmacy Benefits Management & Enterprise Health Platform

Capital Rx is a New York-based health technology company offering a transparent pharmacy benefits management (PBM) platform and enterprise health ecosystem (JUDI) for self-insured employers and health plans; raised $109M Series C in 2022;

AI VisibilityBeta
Overall Score
C52
Category Rank
#318 of 596
AI Consensus
73%
Trend
stable
Per Platform
ChatGPT
54
Perplexity
57
Gemini
46

About

Capital Rx is a New York-based health technology company founded in 2017 by AJ Loiacono and Justin Vattimo. It operates as a transparent pharmacy benefits manager (PBM) and health platform for self-insured employers and health plans, positioned as an alternative to the three dominant incumbent PBMs — CVS Caremark, Express Scripts, and OptumRx — whose bundled pricing models have faced sustained criticism for opacity and misaligned rebate incentives. Capital Rx's core differentiator is its CPEC (Clearinghouse PBM Employer Coalition) pricing model, which passes drug rebates and discounts directly to plan sponsors rather than retaining them as revenue — a structurally transparent approach that the company claims delivers demonstrable cost savings over traditional PBM arrangements.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

52
Overall Score
93
#318
Category Rank
#1
73
AI Consensus
80
stable
Trend
stable
54
ChatGPT
94
57
Perplexity
89
46
Gemini
94
48
Claude
92
50
Grok
98

Key Details

Category
Pharmacy Benefits Management & Enterprise Health Platform
Enterprise
Tier
Challenger
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.